130 Views | 112 Downloads
Correspondence and reprints to: Jeannie Visootsak, MD, 2165 N. Decatur Road, Decatur, GA 30033, Phone: 404.778.8590; FAX: 404.778.8562, jvisoot@emory.edu
We would like to thank the Fragile X Association of Georgia for their support of individuals with Fragile X syndrome and their families.
The authors declare no conflicts of interest.
Supported by National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development (1K23HD058043-01A1 to J.V.) and Fragile X Association of Georgia (to T.A.).
J.V. and E.B-K. receive grant support from Novartis and Roche to conduct clinical trials and consult on use of mGluR5 blockers in individuals with FXS.
E.B-K. has received funding from Asuragen, Inc to develop testing standards for diagnosis of FXS.
© 2014 Elsevier Inc. All rights reserved.